These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 31120815)

  • 1. Cardiac Implantable Electronic Device Therapy in Heart Failure.
    Hussein AA; Wilkoff BL
    Circ Res; 2019 May; 124(11):1584-1597. PubMed ID: 31120815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Effectiveness of Cardiac Resynchronization Therapy Among Patients With Heart Failure and Atrial Fibrillation: Findings From the National Cardiovascular Data Registry's Implantable Cardioverter-Defibrillator Registry.
    Khazanie P; Greiner MA; Al-Khatib SM; Piccini JP; Turakhia MP; Varosy PD; Masoudi FA; Curtis LH; Hernandez AF;
    Circ Heart Fail; 2016 Jun; 9(6):. PubMed ID: 27296396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary Prevention Implantable Cardioverter Defibrillator (ICD) Therapy in Women-Data From a Multicenter French Registry.
    Providência R; Marijon E; Lambiase PD; Bouzeman A; Defaye P; Klug D; Amet D; Perier MC; Gras D; Algalarrondo V; Deharo JC; Leclercq C; Fauchier L; Babuty D; Bordachar P; Sadoul N; Piot O; Boveda S
    J Am Heart Assoc; 2016 Feb; 5(2):. PubMed ID: 26873687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incremental benefit of cardiac resynchronisation therapy with versus without a defibrillator.
    Martens P; Verbrugge FH; Nijst P; Dupont M; Nuyens D; Herendael HV; Rivero-Ayerza M; Tang WH; Mullens W
    Heart; 2017 Dec; 103(24):1977-1984. PubMed ID: 28716973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors for early mortality and arrhythmic events in patients with cardiac resynchronization therapy with defibrillator: A two center cohort study.
    Gunten SV; Theuns DA; Kühne M; Reichlin T; Sticherling C; Schaer B
    Cardiol J; 2019; 26(6):711-716. PubMed ID: 30484267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors and the effect of cardiac resynchronization therapy on cardiac and non-cardiac mortality in MADIT-CRT.
    Perkiomaki JS; Ruwald AC; Kutyifa V; Ruwald MH; Mcnitt S; Polonsky B; Goldstein RE; Haigney MC; Krone RJ; Zareba W; Moss AJ;
    Europace; 2015 Dec; 17(12):1816-22. PubMed ID: 26071234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Compelling First-Line Drug and Device Therapies for the Prevention of Sudden Death in Patients With Chronic Heart Failure and a Reduced Ejection Fraction Who Are Candidates for an Implantable Cardioverter-Defibrillator.
    Packer M
    Circ Arrhythm Electrophysiol; 2019 Jun; 12(6):e007430. PubMed ID: 31159583
    [No Abstract]   [Full Text] [Related]  

  • 8. Sex differences in implantable cardioverter-defibrillator implantation indications and outcomes: lessons from the Nationwide Israeli-ICD Registry.
    Amit G; Suleiman M; Konstantino Y; Luria D; Kazatsker M; Chetboun I; Haim M; Gavrielov-Yusim N; Goldenberg I; Glikson M;
    Europace; 2014 Aug; 16(8):1175-80. PubMed ID: 24554524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Battery longevity of implantable cardioverter-defibrillators and cardiac resynchronization therapy defibrillators: technical, clinical and economic aspects. An expert review paper from EHRA.
    Boriani G; Merino J; Wright DJ; Gadler F; Schaer B; Landolina M
    Europace; 2018 Dec; 20(12):1882-1897. PubMed ID: 29757390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An individualized left ventricular lead-targeting strategy improves long-term survival of cardiac resynchronization therapy patients and influences the benefit of the implantable cardioverter-defibrillator: a long-term follow-up of the TARGET study.
    Barra S; Yu E; Khan F; Dutka D; Virdee M
    J Cardiovasc Med (Hagerstown); 2017 Jul; 18(7):553-555. PubMed ID: 27136703
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy of Pharmacologic and Cardiac Implantable Electronic Device Therapies in Patients With Heart Failure and Reduced Ejection Fraction: A Systematic Review and Network Meta-Analysis.
    Tseng AS; Kunze KL; Lee JZ; Amin M; Neville MR; Almader-Douglas D; Killu AM; Madhavan M; Cha YM; Asirvatham SJ; Friedman PA; Gersh BJ; Mulpuru SK
    Circ Arrhythm Electrophysiol; 2019 Jun; 12(6):e006951. PubMed ID: 31159582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Saving lives and reducing inappropriate device therapy: the MADIT family of implantable cardioverter-defibrillator and cardiac resynchronization therapy trials.
    Moss AJ
    Cardiol J; 2013; 20(3):217-9. PubMed ID: 23788293
    [No Abstract]   [Full Text] [Related]  

  • 13. Atrial fibrillation in cardiac resynchronization therapy with a defibrillator: a risk factor for mortality, appropriate and inappropriate shocks.
    van Boven N; Theuns D; Bogaard K; Ruiter J; Kimman G; Berman L; VAN DER Ploeg T; Kardys I; Umans V
    J Cardiovasc Electrophysiol; 2013 Oct; 24(10):1116-22. PubMed ID: 23889733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cause-of-death analysis in patients with cardiac resynchronization therapy with or without a defibrillator: a systematic review and proportional meta-analysis.
    Barra S; Providência R; Duehmke R; Boveda S; Begley D; Grace A; Narayanan K; Tang A; Marijon E; Agarwal S
    Europace; 2018 Mar; 20(3):481-491. PubMed ID: 28666319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of extending device longevity on the long-term costs of implantable cardioverter-defibrillator therapy: a modelling study with a 15-year time horizon.
    Boriani G; Braunschweig F; Deharo JC; Leyva F; Lubinski A; Lazzaro C
    Europace; 2013 Oct; 15(10):1453-62. PubMed ID: 23696624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complications in recipients of cardioverter-defibrillator or cardiac resynchronization therapy: Insights from Silesian Center Defibrillator registry.
    Tajstra M; Gadula-Gacek E; Kurek A; Adamowicz-Czoch E; Olszowski D; Ostręga M; Ciślak A; Pyka Ł; Hawranek M; Lekston A; Poloński L; Gąsior M
    Cardiol J; 2017; 24(5):515-522. PubMed ID: 27734455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patients upgraded to cardiac resynchronization therapy due to pacing-induced cardiomyopathy are at low risk of life-threatening ventricular arrhythmias: a long-term cause-of-death analysis.
    Barra S; Duehmke R; Providencia R; Marijon E; Boveda S; Virdee M; Heck P; Fynn S; Begley D; Grace A; Agarwal S
    Europace; 2018 Jan; 20(1):89-96. PubMed ID: 28031276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ventricular electrical delay as a predictor of arrhythmias in patients with cardiac resynchronization implantable cardioverter defibrillator.
    Elsaid O; Gulati V; Tecson K; Friedman M; Kluger J
    Scand Cardiovasc J; 2018 Dec; 52(6):356-361. PubMed ID: 30570402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sex Differences in Device Therapies for Ventricular Arrhythmias or Death in the Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy (MADIT-CRT) Trial.
    Tompkins CM; Kutyifa V; Arshad A; McNitt S; Polonsky B; Wang PJ; Moss AJ; Zareba W
    J Cardiovasc Electrophysiol; 2015 Aug; 26(8):862-871. PubMed ID: 25929699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prophylactic implantable cardioverter defibrillators for primary prevention: From implantation to heart transplantation.
    Algalarrondo V; Perault R; Bories MC; Narayanan K; Garcia R; Combes N; Perier MC; Defaye P; Sadoul N; Gras D; Klug D; Bordachar P; Fauchier L; Deharo JC; Leclercq C; Boveda S; Marijon E; Babuty D;
    Arch Cardiovasc Dis; 2018 Dec; 111(12):758-765. PubMed ID: 30078651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.